Clinical Trial Update: B/F/TAF to DTG/3TC Switch Study [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating switching from B/F/TAF to DTG/3TC in people with HIV-1 infection; the study is currently ACTIVE_NOT_RECRUITING.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• BIKTARVY (BICTEGRAVIR SODIUM, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE FUMARATE)
• Dovato (dolutegravir/lamivudine)

Snippet

Sponsor: University of Nairobi | Conditions: HIV-1-infection | Phase 3 | Status: ACTIVE_NOT_RECRUITING